Texas Permanent School Fund raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 14.1% during the second quarter, Holdings Channel reports. The fund owned 49,733 shares of the company’s stock after buying an additional 6,134 shares during the period. Texas Permanent School Fund’s holdings in Myriad Genetics were worth $1,285,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in MYGN. Albert D Mason Inc. raised its stake in shares of Myriad Genetics by 1.5% in the first quarter. Albert D Mason Inc. now owns 16,382 shares of the company’s stock valued at $315,000 after buying an additional 250 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its stake in shares of Myriad Genetics by 1.7% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 21,733 shares of the company’s stock valued at $417,000 after buying an additional 357 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Myriad Genetics by 3.1% in the second quarter. Municipal Employees Retirement System of Michigan now owns 16,080 shares of the company’s stock valued at $416,000 after buying an additional 490 shares during the last quarter. Aperio Group LLC raised its stake in shares of Myriad Genetics by 4.6% in the second quarter. Aperio Group LLC now owns 12,129 shares of the company’s stock valued at $313,000 after buying an additional 534 shares during the last quarter. Finally, Creative Planning raised its stake in shares of Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock valued at $122,000 after buying an additional 671 shares during the last quarter.

Myriad Genetics, Inc. (MYGN) opened at 27.86 on Friday. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $28.39. The company has a market cap of $1.91 billion, a price-to-earnings ratio of 87.34 and a beta of 0.31. The firm has a 50-day moving average price of $25.39 and a 200 day moving average price of $21.26.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.04. The business had revenue of $200.50 million for the quarter, compared to analysts’ expectations of $193.71 million. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.36 EPS. Equities analysts expect that Myriad Genetics, Inc. will post $1.02 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/18/myriad-genetics-inc-mygn-shares-bought-by-texas-permanent-school-fund.html.

Several equities research analysts recently commented on the company. Jefferies Group LLC restated a “hold” rating and set a $21.00 target price (up previously from $18.00) on shares of Myriad Genetics in a research report on Wednesday, May 3rd. BidaskClub lowered Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Barclays PLC cut their target price on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 9th. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Monday, July 17th. Finally, Cowen and Company restated a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a research report on Friday, July 14th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. Myriad Genetics presently has an average rating of “Hold” and an average target price of $21.78.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.